Drug

Study

ORR

mPFS

Reference

Atezolizumab

NCT024093342 (IMPower 110), N = 572 (phase III), atezolizumab vs. chemotherapy (PL-L1 ≥ 50%)

38.3% vs. 26.8%

8.1 vs. 5.0 mo.

Herbst et al. 2020 [14]

Pembrolizumab

NCT02142738 (KeyNote-024), N = 305 (phase III), pembrolizumab vs. chemotherapy (PD-L1 ≥ 50%)

44.8% vs. 27.8%

10.3 vs. 6.0 mo.

Reck et al. 2016 [15]

Nivolumab

NCT02041533 (Checkmate-026), N = 541 (phase III), nivolumab vs. chemotherapy (PD-L1 > 5%)

26% vs. 31%

4.2 vs. 5.9 mo.

Carbane et al. 2017 [16]

Durvalumab

NCT02453282 (MYSTIC), N = 1118 (phase III), durvalumab vs. durvalumab + tremelimumab vs. chemotherapy

35.6%* vs. 34.4% vs. 37.7%

4.2* vs. 3.0 vs. 5.4 mo.

Rizvi et al. 2020 [17]